New Alzheimer's drug trial uses eye scans to track brain changes
NCT ID NCT07604896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called lecanemab in 200 people with early-stage Alzheimer's. Participants receive either lecanemab or standard care for 24 months. Researchers use eye and brain scans along with memory tests to see if the drug slows the disease and to check for side effects like brain swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••